VTVT · vTv Therapeutics Inc.
Market Cap
$127.95M
Shares
3.95M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$32.00
Open$32.25
Day$31.35–32.25
52W close$18.31–42.72
Avg vol 30d92K
Short int166K · 4.2% float · 1.6d
Short vol73%
DataNov 2023–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on Nov 21, 2023; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−7%
below
Price vs 50-day avg
−4%
below
RSI (14)
45
neutral
MACD trend
Positive
52-week position
56%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
−9%
trailing
YTD return
−20%
this year
Relative strength
−22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $33 › 200d $34 — 200d above 50d
Institutional flow
Accumulating
+29% holders QoQ · +17 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.20% of float · ▲ +0.1% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
45 holders — near 3-yr high, broad support
Squeeze score
55
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
Free cash flow
$-25.3M
Balance sheet
$3.3M
net debt
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−32%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−7%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
45
Neutral
MACD trend
Positive
Bullish
52-week position
56%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $33 › 200d $34 — 200d above 50d
Institutional flow
Accumulating
+29% holders QoQ · +17 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.20% of float · ▲ +0.1% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
45 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $18
Now $32 · 56%
Range high $43
vs 200-day avg -7%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VTVT
this stock
vTv Therapeutics Inc.
|
$127.95M | -20.0% | -100.0% | — | 4.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.1% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +3.5% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
Raw-price comparisons begin at the captured split on Nov 21, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VTVT | -5.6% | -1.2% | -8.6% | -1.1% | -20.0% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -6.1% | -2.4% | -21.9% | -3.8% | -32.5% |